With Arena Pharmaceuticals (NASDAQ: ARNA ) and Eisai still waiting for their obesity drug Belviq to complete DEA scheduling, it was their chief rival VIVUS (NASDAQ: VVUS ) that made news today. All eyes were on VIVUS' decision to take out a loan that could amount to $110 million.
But why is this necessary at all? Does the company need more capital to enhance its marketing strategy for the obesity drug Qsymia, or is this a signal that VIVUS is currently in a difficult financial situation? Health-care analyst Max Macaluso sheds light on this news in the following video.
Is now the time to sell VIVUS?
VIVUS' shares were clobbered after Qsymia's dismal launch. Investors everywhere are wondering whether the tide will turn for this fledgling drugmaker or if now is the perfect time to sell. In a new premium research report, the Fool's top health-care contributor breaks down this complex story and explains the details VIVUS investors must know -- including reasons to buy and sell. To find out more about this premium report click here now.